Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow-Up of Boceprevir or Narlaprevir in Chronic Hepatitis C
NCT00689390Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2007
- Primary completion
- Oct 2014
- Modality
- Orthosteric Ligands
01
Overview
A Phase 3 trial of boceprevir, narlaprevir in hepatitis C (HCV), sponsored by Merck & Co.. Started Feb 2007; status: terminated.
02
Drugs
boceprevirnarlaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00689390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00689390.